Activated S6K causes crosstalk on the Ras/Raf/MAPK signaling pathway, and further diminishes the inhibitory effect of sorafenib on HCC, leading to sorafenib resistance to HCC [32, 34]. This evidence concerns the gene RAF1 and hepatocellular carcinoma.